The antiviral pill, brand named Lagevrio, could not demonstrate benefits in treatment of COVID patients who do not need oxygen support and are at risk of their disease worsening, the European Medicines Agency said.
https://www.pharmalive.com/wp-content/uploads/2021/06/U.S.-signs-1.2-bln-deal-for-1.7-mln-courses-of-Mercks-experimental-COVID-19-drug-Reuters-6-9-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-02-24 08:19:432023-02-24 09:20:23EU regulator recommends against approval for Merck’s COVID pill for adults